FDA Grants Orphan Drug Designation to Quemliclustat in Pancreatic Cancer
Quemliclustat plus gemcitabine and nab-paclitaxel chemotherapy outperformed median OS benchmarks in patients with metastatic PDAC.
Related Articles
Tarlatamab Shows Promising Real-World Activity in Extensive-Stage SCLC
Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.
AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer-From Biology to Breakthrough Therapies
Meeting overview for AACR Special Conference in Cancer Research Discovery and Innovation in Pediatric Cancer- From Biology to Breakthrough Therapies
Nivolumab Plus Relatlimab Shows Long-Term EFS Benefit in Advanced Melanoma
The B7-H3–low and TIGIT-high biosignatures correlated with superior event-free survival outcomes in those with melanoma treated with the combination.
Givastomig Regimen Yields Preliminary Activity in Gastric/GEJ Cancers
Phase 1b data show antitumor activity with the givastomig combination across a wide range of CLDN18.2 expression.
Immunotherapy, Novel Agents May Reshape the Early Breast Cancer Landscape
Heather McArthur, MD, focused on current and future strategies for treating early-stage breast cancer.
Large‐scale validation study of an improved semiautonomous urine cytology assessment tool: AutoParis‐X
The authors developed a publicly available, open-source, interactive web application featuring a simple, easy-to-use display for examining urine cytology whole-slide images and determining the atypia…
All Lung Cancer Resources
All Non-Hodgkin Lymphomas (NHL) resources for patients, their families, and caregivers available through NCCN.
Avutometinib/Defactinib Display Safety, Efficacy in Ovarian Cancer Subtype
Among 115 patients treated with avutometinib and defactinib, only 5 deaths occurred in the study, none of which were related to study treatment.
Developers Resubmit BLA for Tab-Cel in EBV+ Lymphoproliferative Disease
The FDA lifted a clinical hold on a new drug application for tabelecleucel as a treatment for EBV-positive lymphoproliferative disease in May 2025.
Anti-BCMA and Anti-GPRC5D BiTEs Show Similar Efficacy in Multiple Myeloma
A real-world analysis of teclistamab, elranatamab, and talquetamab showed comparable outcomes in relapsed or refractory multiple myeloma.